Biomarkers in Alzheimer's disease drug development.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21052077.
- Also identified by DOI 10.1038/nm.2221.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Biomarkers may be of great value in Alzheimer's disease drug development to select the most optimal drug candidates for large and expensive phase 3 clinical trials. Biomarkers will also be important to provide evidence that a drug affects the underlying pathophysiology of the disease, which, together with a beneficial effect on the clinical course, will be essential for labeling the drug as having a disease-modifying effect.
Medical subject headings
- Alzheimer Disease
- Biomarkers
- Drug Discovery